A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma

Anna Nowak, C. Brown, Michael Millward, Jenette Creaney, Michael Byrne, B. Hughes, G. Kremmidiotis, D.C. Bibby, A.F. Leske, P.L.R. Mitchell, N. Pavlakis, M. Boyer, M.R. Stockler

Research output: Contribution to journalArticlepeer-review

45 Citations (Scopus)
Original languageEnglish
Pages (from-to)422-427
JournalLung Cancer
Issue number3
Publication statusPublished - 2013

Cite this